West Pharmaceutical Services, Inc. (NYSE:WST) Shares Purchased by Raymond James & Associates

Raymond James & Associates boosted its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 2.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 77,545 shares of the medical instruments supplier’s stock after acquiring an additional 1,709 shares during the period. Raymond James & Associates’ holdings in West Pharmaceutical Services were worth $23,276,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of WST. Fidelis Capital Partners LLC acquired a new position in shares of West Pharmaceutical Services during the 1st quarter worth approximately $27,000. Crewe Advisors LLC lifted its position in shares of West Pharmaceutical Services by 322.7% in the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 71 shares in the last quarter. ORG Partners LLC boosted its stake in shares of West Pharmaceutical Services by 820.0% during the first quarter. ORG Partners LLC now owns 138 shares of the medical instruments supplier’s stock valued at $55,000 after acquiring an additional 123 shares during the last quarter. Quest Partners LLC increased its position in West Pharmaceutical Services by 5,633.3% during the 2nd quarter. Quest Partners LLC now owns 172 shares of the medical instruments supplier’s stock worth $57,000 after purchasing an additional 169 shares in the last quarter. Finally, LRI Investments LLC acquired a new position in West Pharmaceutical Services in the 1st quarter valued at about $86,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Insider Transactions at West Pharmaceutical Services

In related news, VP Charles Witherspoon sold 1,029 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the transaction, the vice president now directly owns 1,478 shares in the company, valued at approximately $443,400. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Price Performance

West Pharmaceutical Services stock opened at $330.65 on Friday. The stock has a market capitalization of $23.99 billion, a P/E ratio of 47.03, a P/E/G ratio of 10.21 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 12-month low of $265.00 and a 12-month high of $413.70. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68. The firm’s 50-day moving average is $300.36 and its two-hundred day moving average is $322.86.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The firm had revenue of $702.10 million for the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The firm’s revenue was down 6.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.11 EPS. Equities analysts predict that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.